Health and Fitness Health and Fitness
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ] - Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ] - Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ] - Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010

Kendall Law Group Investigates King Pharmaceuticals, Inc. Acquisition for Shareholders


//health-fitness.news-articles.net/content/2010/ .. aceuticals-inc-acquisition-for-shareholders.html
Published in Health and Fitness on Tuesday, October 12th 2010 at 6:45 GMT by Market Wire   Print publication without navigation


DALLAS--([ BUSINESS WIRE ])--[ Kendall Law Group ], led by former federal judge Joe Kendall, is investigating King Pharmaceuticals, Inc. (NYSE: KG) for shareholders in connection with the proposed acquisition by Pfizer. The national securities firma™s investigation seeks to determine whether King Pharmaceuticals and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a King Pharmaceuticals shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [ skendall@kendalllawgroup.com ].

On October 12, 2010, the companies announced the definitive merger agreement under which King Pharmaceuticals would be acquired by Pfizer in a transaction valued at approximately $3.6 billion. Under the terms of the agreement, King Pharmaceuticals stockholders will receive $14.25 in cash for each share of King Pharmaceuticals/KG common stock held. According to Thompson/First Call, at least one analyst has set a price target of $15.00 per share for King Pharmaceuticals stock. Additionally, King Pharmaceuticals stock was trading for over $13.00 earlier this year. Due to these factors, the firm believes the transaction significantly undervalues the company.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.


Publication Contributing Sources